The primary purpose of this study is:~to determine if 8 weeks of topical remetinostat gel applied 3 times daily (TID) under occlusion will suppress SCC growth~to determine the overall response rate (ORR) of SCCs after 8 weeks of treatment with topical remetinostat gel 1%, as measured by at least 30% decrease in greatest area (in mm2).~Subjects with at least 1 biopsy-proven cutaneous SCC will be recruited for this study.~Subjects will apply remetinostat gel 1% to at least 1 SCC.~Non-invasive cutaneous SCC lesions, including Bowen's disease, are also eligible for this study~There is 1 treatment option: Topical remetinostat gel 1% applied 3 times daily.~The study is a single arm, open label design~For purposes of ClinicalTrials.gov, there is no secondary outcome.
The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.